tetano
Editor, Senior Moderator
J Biol Chem
. 2021 May 6;100759.
doi: 10.1016/j.jbc.2021.100759. Online ahead of print.
The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection
Anthony J Carlos[SUP] 1 [/SUP], Dat P Ha[SUP] 1 [/SUP], Da-Wei Yeh[SUP] 2 [/SUP], Richard Van Krieken[SUP] 1 [/SUP], Chun-Chih Tseng[SUP] 1 [/SUP], Pu Zhang[SUP] 1 [/SUP], Parkash Gill[SUP] 3 [/SUP], Keigo Machida[SUP] 2 [/SUP], Amy S Lee[SUP] 4 [/SUP]
Affiliations
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 global pandemic, utilizes the host receptor angiotensin-converting enzyme 2 (ACE2) for viral entry. However, other host factors might also play important roles in SARS-CoV-2 infection, providing new directions for antiviral treatments. GRP78 is a stress-inducible chaperone important for entry and infectivity for many viruses. Recent molecular docking analyses revealed putative interaction between GRP78 and the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein (SARS-2-S). Here we report that GRP78 can form a complex with SARS-2-S and ACE2 on the surface and at the perinuclear region typical of the endoplasmic reticulum in VeroE6-ACE2 cells, and that the substrate binding domain of GRP78 is critical for this interaction. In vitro binding studies further confirmed that GRP78 can directly bind to the RBD of SARS-2-S and ACE2. To investigate the role of GRP78 in this complex, we knocked down GRP78 in VeroE6-ACE2 cells. Loss of GRP78 markedly reduced cell surface ACE2 expression and led to activation of markers of the unfolded protein response. Treatment of lung epithelial cells with a humanized monoclonal antibody (hMAb159) selected for its safe clinical profile in preclinical models, depleted cell surface GRP78 and reduced cell surface ACE2 expression, as well as SARS-2-S-driven viral entry and SARS-CoV-2 infection in vitro. Our data suggest that GRP78 is an important host auxiliary factor for SARS-CoV-2 entry and infection and a potential target to combat this novel pathogen and other viruses that utilize GRP78 in combination therapy.
Keywords: ACE2; Antibody; GRP78; SARS-CoV-2; Spike Protein.
. 2021 May 6;100759.
doi: 10.1016/j.jbc.2021.100759. Online ahead of print.
The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection
Anthony J Carlos[SUP] 1 [/SUP], Dat P Ha[SUP] 1 [/SUP], Da-Wei Yeh[SUP] 2 [/SUP], Richard Van Krieken[SUP] 1 [/SUP], Chun-Chih Tseng[SUP] 1 [/SUP], Pu Zhang[SUP] 1 [/SUP], Parkash Gill[SUP] 3 [/SUP], Keigo Machida[SUP] 2 [/SUP], Amy S Lee[SUP] 4 [/SUP]
Affiliations
- PMID: 33965375
- DOI: 10.1016/j.jbc.2021.100759
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 global pandemic, utilizes the host receptor angiotensin-converting enzyme 2 (ACE2) for viral entry. However, other host factors might also play important roles in SARS-CoV-2 infection, providing new directions for antiviral treatments. GRP78 is a stress-inducible chaperone important for entry and infectivity for many viruses. Recent molecular docking analyses revealed putative interaction between GRP78 and the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein (SARS-2-S). Here we report that GRP78 can form a complex with SARS-2-S and ACE2 on the surface and at the perinuclear region typical of the endoplasmic reticulum in VeroE6-ACE2 cells, and that the substrate binding domain of GRP78 is critical for this interaction. In vitro binding studies further confirmed that GRP78 can directly bind to the RBD of SARS-2-S and ACE2. To investigate the role of GRP78 in this complex, we knocked down GRP78 in VeroE6-ACE2 cells. Loss of GRP78 markedly reduced cell surface ACE2 expression and led to activation of markers of the unfolded protein response. Treatment of lung epithelial cells with a humanized monoclonal antibody (hMAb159) selected for its safe clinical profile in preclinical models, depleted cell surface GRP78 and reduced cell surface ACE2 expression, as well as SARS-2-S-driven viral entry and SARS-CoV-2 infection in vitro. Our data suggest that GRP78 is an important host auxiliary factor for SARS-CoV-2 entry and infection and a potential target to combat this novel pathogen and other viruses that utilize GRP78 in combination therapy.
Keywords: ACE2; Antibody; GRP78; SARS-CoV-2; Spike Protein.